Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study) - Sorbonne Université
Journal Articles Journal of Infection Year : 2022

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)

Fichier principal
Vignette du fichier
10.1016_j.jinf.2022.04.010.pdf (714.94 Ko) Télécharger le fichier
Origin Files produced by the author(s)

Dates and versions

hal-03784773 , version 1 (23-09-2022)

Identifiers

Cite

Guillaume Martin-Blondel, Anne-Genevieve Marcelin, Cathia Soulié, Sofia Kaisaridi, Clovis Lusivika-Nzinga, et al.. Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). Journal of Infection, 2022, 84 (6), pp.e101-e104. ⟨10.1016/j.jinf.2022.04.010⟩. ⟨hal-03784773⟩
78 View
70 Download

Altmetric

Share

More